Table 4:
Multi-drug resistance (MDR) among the 5 participants with PI DRMs on 2nd line regimens.
| Duration | ||||||
|---|---|---|---|---|---|---|
| #Number | Age (years) |
Gender | On 2nd line ART prior to enrolment (years) |
PI DRMs | NRTI DRMs |
NNRTI DRMs |
| 1 | 18 | Male | 4 | M46I, I54V, N88S | M184V, T215Y | Y181C, G190A, H222Y |
| 2 | 12 | Male | 4 | M46I, I84IV, N88NS | M184V, K70R, T215F, K219Q, D67N, T69D | V108I, Y181C |
| 3 | 17 | Female | 4 | V82M | M184V, K70R, D67G, T69D, K219Q | A98G, K101E, Y181C, G190A |
| 4 | 15 | Male | 1 | M46I | M184V, K65R, A62V | A98G, Y181C, G190A |
| 5 | 21 | Female | 3 | M46I, L90M | M184V, M41L, K70N, L74I, V75T, L210W, T215Y | K101E, E138A, G190A |
PI protease inhibitor; NRTIs nucleoside/nucleotide reverse transcriptase inhibitors; DRMs drug resistance mutations; NNRTIs non NRTIs.